Most of the deaths due to cancer affect the elderly population. The numerous and often underestimated co-morbidities, which weaken elderly cancer patients, interfere with the validity of medical decisions, by raising questions related to the true benefits of the suggested radiotherapy or chemotherapy, in the medium or long term. This leads, sometimes wrongly, either to an absence of oncologic treatment, or to excessive or aggressive therapeutic proposals. The review of the literature leads us to suggest that a global geriatric evaluation should systematically be done to oncologic patients over seventy, with the help of proven tools, in order to offer an appropriate and optimal oncologic treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Hygienic assessment and prospects for the use of protein-based sweeteners in food production].
Vopr Pitan
January 2025
JSC EFKO Management Company, 115035, Moscow, Russian Federation.
The analysis of the morbidity in the population of the Russian Federation showed the presence of a significant number of people with chronic non-infection pathologies, including obesity, diabetes mellitus, whose diet should include food with reduced energy value. For this purpose, food containing sweeteners are widely used. At the same time, the range of sweeteners permitted for the usage in food industry does not always allow achieving the desired technological effect.
View Article and Find Full Text PDFValidation of the PANAMA-Score for Survival and Benefit of Adjuvant Therapy in Patients with Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX.
Ann Surg
January 2025
Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Aim: To validate the prognostic value of the PAncreatic NeoAdjuvant MAssachusetts (PANAMA)-score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection of pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant FOLFIRINOX.
Background: The PANAMA-score was developed to guide prognostication in patients after neoadjuvant therapy and resection for PDAC. As this score focuses on the risk for residual disease after resection, it might also be able to select patients who benefit from adjuvant after neoadjuvant therapy.
Case report: Relapse of intrathyroidal parathyroid carcinoma in a patient with novel variants in and genes.
Front Oncol
January 2025
Administration, Endocrinology Research Center, Moscow, Russia.
Parathyroid carcinoma (PC) is one of the rarest malignant neoplasms of the human endocrine system, with a prevalence of approximately 0.005% of all oncological diseases. Despite its indolent course, PC generally relapses in about 40%-60% of cases.
View Article and Find Full Text PDFImplications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review.
BMJ Oncol
May 2024
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Transgender and gender-diverse (TGD) individuals face an elevated risk of cancer in comparison with the general population. This increased risk is primarily attributed to an imbalanced exposure to modifiable risk factors and a limited adherence to cancer screening programmes, stemming from historical social and economic marginalisation. Consequently, these factors contribute to poorer clinical outcomes in terms of cancer diagnosis and mortality.
View Article and Find Full Text PDFA bibliometric study on the impact of gut microbiota on the efficacy of immune checkpoint inhibitors in cancer patients: analysis of the top 100 cited articles.
Front Immunol
January 2025
School of Basic Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Background: Immune checkpoint inhibitors (ICIs) have transformed oncological treatment by modulating immune responses against tumors. However, their efficacy is subject to inter-patient variability and is associated with immune-related adverse events (irAEs). The human gut microbiota, a complex microbial ecosystem, is increasingly implicated in modulating responses to ICIs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!